US DoD agrees deal with German firm for COVID-19 therapeutics

22 July 2020
evotec-large

The Seattle-based subsidiary of Hamburg, Germany-based Evotec (EVT: Xetra) will develop COVID-19 antibodies for the US Department of Defense (DoD), under an $18.2 million contract.

Shares in the firm were lifted over 3% in morning trading in Germany.

The program aims to rapidly and efficiently deliver the monoclonal antibodies for use in combating the growing impact of the coronavirus in the USA.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology